I liked the fact that he had the other members of the mgt. team on the call. He also sounded like he was very knowledgable and was comfortably in command of the company.
Except for a loss of $845,000 attributable to noncontrolling interests! I'm not sure what that was but the 3 plants with all the expenses earned 2 cents which is double what was reported. I hope mgt. has a good explanation of what the loss was do to.
Good point! During CRY's bull run in 2008, we actually had doctors on this board raving about some of CRY's products! ( I wouldn't be surprised to see that again especially in 2014.) I also think that one of the reasons CRY sells so much Bioglue is Cardial Vascular surgeons really appreciate the fact that CRY goes the extra mile with the tissue business. CRY is about the only guys in the country that have it.
I have a much different view than the 3 other main posters on this board. I think CRY has a number of growth drivers which could be very positive for the company going forward. Some new ones were even mentioned in the latest CC. Some of these include:
1) PERCLOT approval FDA in 2014. What is cool is international sales are starting to excelerate and a German has written a very positive paper on the products advantages versus the competition.
2) CRY expects European approval of the HeRO Graft in the 2nd quarter.
3) The HeRO Graft sounds like it has good growth possibilities as the FDA granted them a very speedy approval of their upgraded higher margined adapter which will be launched in the 4th quarter.
4) Sales of Bioglue in Japan are increasing and CRY plans to file for expanded uses. In addition, CRY plans to file for Perclot approval in Japan later this year.
5) The HeRO Graft has attracted new surgeons and other health care professionals to the company and these new clients are interested in CRY's other products.
6) CRY mentioned that Valve Exchange could get European approval for their new heart valve later in 2013! As Stated earlier this is my kicker because CRY has the rights to sell this product in Europe! ( It's not about FDA approval.) There could be big numbers here in the future that are in anyone's forecast.
7) CRY produces substancial free cash flow and has been buying back a lot more shares over the last couple shares than they have issued to management.
CRY is a large position for me and I've been accumulating more shares on weakness so I'm biased. Do your own due diligence.
Watch the shorts start screaming when earnings come out. Remember 80% of sales are outside the United States in places like Russia where sales are booming.
It's right on yahoo news items. Bill talks about HLF having fewer complaints than other direct marketing companies like Tupperware and Avon! He says they have great products. His mother-in-law lost 50 pounds. You should go to a meeting! It's like an alcoholic anonomous meeting for over weight people.
I could be wrong but it looks to me that if you look at the analysts' estimates on Yahoo, there is one person who dramatically raised estimates for the March qtr. and 2013 year!
I could be wrong and so could Yahoo Do your own due diligence.
HeRO Graft is a big one. Mgt. confirmed my thought that lots of doctors are attending their training/seminars by saying 75 will attend the conference on April 22nd. That's even better than I thought plus they already got the higher margined product approved by the FDA. Then Perclot is coming without a doubt and it works better than anything else I've heard about. The third Is my kicker on the Valve Exchange heart valve. I'm not as postive on that but it sounds like it has blockbuster long term potential. I don't know what the figures are in Europe but think the number of heart valve surgeries is around 85,000 in the US.
Do your own due diligence.
That's one of the reasons you should be buying. The other is CRY has three major catalysts on a going forward basis. I bet you right now that CRY will be at least $8 a share in 2014 which will significantly outperform the market and it will probably hit 10 in 2014.
This is strictly my own opinion. Do your own due diligence.
This is the fastest FDA approval I've seen CRY get. The FDA must really like the Hero graft! I could be wrong but I think this modification of the Hero graft raises its gross margin 5 to 10%. If memory serves me correctly it is from 63% to 71% or so.
It's called ICAHN UNLEASHED. I thought it was a great read and talks about how ICAHN invested over the years and built his wealth. It also talks about all his current streams of income and what a powerhouse he is.
I was going to reply yesterday that the Hero Graft sales figures might be really light es[ecially as you look later in the year because it looked to me like CRY has 7 three day training type sessions on this subject scheduled throughtout the year. So they must be getting a big response from doctors throughtout the country.
It's a lot more than 2% of the problem! Did you know that OB/GYNs pay between $100,000 to $200,000 per year in high cost states just for Malpractice? Many surgeons pay between $100, 000 to $300,000 . As a result lots of unneccesary expenses tests and other costs are added to every single proceedure! The legal problem is a huge part of it.
The no brainer change would be to reform the legal system! It is obscene what doctor's pay for malpractice insurance compared to Europe! The problem is half the politicians including the president are lawyers!
Liked the CC and liked the 4th quarter report. Already own quite a bit but had to buy more when the price is still low! I wouldn't be surprised if the analysts that follow the company become more bullish as time goes forward.
I have visited the plant site at Neal Hot Springs before the plant was built, during construction and after they started selling the power in late January. My buddies and I were impressed.
Do your own due diligence.
Looks to me like HTM had 4th qtr. revenue of 5.3 million and a profit of about $300,000. Since Neal Hot Springs didn't get turned on until mid November and was basically just starting up, I'd say that's pretty good.
Yes I did attend probably the best college in accounting west of the Mississippi. One of my professors who I took 4 courses from finished number two in the nation on the CPA exam. That was Frank Weinberger. Both Frank and his buddy Ed Celeski were so good that a number of the students were on the edge of their seats. They now have a building at my old school named after them.
Ed Celeski was a specialist in cost accounting. I took two classes on cost accounting from Ed. Probably Ed's best message was the dangers of cost allocation in making business decissions. His example was four Chinese grocery stores owned by the same family. If you used cost allocation it looked like two of the gocery stores were losing money and it would be a smart idea to close them. However if you did the company would end up losing money. The reason is the important number is contribution!!!!!!!!!! If a division is making a contribution towards fixed overhead then it is a viable part of overall profitability of the business!!!!!!!
Now that doesn't mean that the division can't be improved or the capital deployed in a better way. It just means that if the division is making a contribution then it is contributing to the overall profitability of the company.